Article
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
European journal of cancer (Oxford, England : 1990) - 17 Jan 2025
Amaral Teresa, Nanz Lena, Higuita Lina Maria Serna, Ascierto Paolo, Berking Carola, Couselo Eva Muñoz, Donia Marco, Dummer Reinhard, Gutzmer Ralf, Haushild Axel, Jalving Mathilde, Lee Rebecca, Lorigan Paul, Marquez-Rodas Ivan, Michelin Olivier, Nathan Paul, Robert Caroline, Schadendorf Dirk, Sobczuk Pawel, Flatz Lukas, Leiter Ulrike, Garbe Claus
Abstract excerpt
BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. METHODS: We conducted a systematic review of real-world...
Topics
Join the communities discussing this publication.